Literature DB >> 8319368

Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.

P Perros1, A L Crombie, J N Matthews, P Kendall-Taylor.   

Abstract

BACKGROUND: The pathogenesis of thyroid-associated ophthalmopathy is thought to be autoimmune, although environmental and genetic factors are also considered to be important. As the morbidity of thyroid-associated ophthalmopathy is considerable and treatment often unsatisfactory, there a need to identify possible predisposing factors.
OBJECTIVE: The study was undertaken in order to ascertain the relationship between age, gender and severity of thyroid-associated ophthalmopathy. PATIENTS: One hundred and one consecutive patients with thyroid-associated ophthalmopathy who presented over a period of 5 years to a combined thyroid-eye clinic.
METHODS: Patients were assessed by grading their inflammatory signs and degree of diplopia, and by measurement of exophthalmos, palpebral aperture, differential intraocular pressure, and visual acuity. On the basis of the above an ophthalmopathy index was devised to grade the overall severity of eye disease.
RESULTS: The mean age was 49.2 years (SD 13.4), the female-to-male ratio was 4.05, and mean ophthalmopathy index 6.49 (SD 3.3). Optic nerve compression was present in 9.9% of patients. There was a positive relationship between age and ophthalmopathy index (P < 0.001); after correcting for age, males had an average ophthalmopathy index 41% greater than that of females.
CONCLUSION: There is an association between severity of thyroid-associated ophthalmopathy and (i) advancing age and (ii) female-to-male ratio, which has not been previously described. Patients over the age of 60 (particularly males) with Graves' disease appear to be at risk of developing severe eye disease.

Entities:  

Mesh:

Year:  1993        PMID: 8319368     DOI: 10.1111/j.1365-2265.1993.tb00516.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  49 in total

Review 1.  Radioiodine and thyroid-associated ophthalmopathy: from the myth to the reality.

Authors:  C Beckers
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  Recent developments in thyroid eye disease.

Authors:  Tom Cawood; Paul Moriarty; Donal O'Shea
Journal:  BMJ       Date:  2004-08-14

3.  The role of thyroid eye disease and other factors in the overcorrection of hypotropia following unilateral adjustable suture recession of the inferior rectus (an American Ophthalmological Society thesis).

Authors:  Natalie C Kerr
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

4.  Incidence and clinical characteristics of pediatric eyelid retraction.

Authors:  Jessica A Olayanju; Gregory J Griepentrog; Brian G Mohney
Journal:  J AAPOS       Date:  2019-06-20       Impact factor: 1.220

Review 5.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

Review 6.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

Review 7.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

8.  Management of patients in a combined thyroid eye clinic in secondary care.

Authors:  J D Benzimra; A G Quinn; T Kersey; D McGrane; L Goss; B Vaidya
Journal:  Int Ophthalmol       Date:  2013-04-03       Impact factor: 2.031

9.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.